Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2019 - 2026)

Atea Pharmaceuticals' Income from Continuing Operations history spans 8 years, with the latest figure at 45440000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 32.59% to 45440000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 169517000.0 through Mar 2026, down 21.53% year-over-year, with the annual reading at 158349000.0 for FY2025, 5.96% up from the prior year.
  • Income from Continuing Operations came in at 45440000.0 for Q1 2026, down from 44867000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 8066000.0 in Q3 2022 to a low of 63169000.0 in Q1 2024.
  • The 5-year median for Income from Continuing Operations is 35467000.0 (2023), against an average of 36708176.47.
  • The largest YoY upside for Income from Continuing Operations was 71.39% in 2022 against a maximum downside of 2136.06% in 2022.
  • Atea Pharmaceuticals' Income from Continuing Operations stood at 34431000.0 in 2022, then fell by 13.75% to 39164000.0 in 2023, then grew by 14.35% to 33543000.0 in 2024, then plummeted by 33.76% to 44867000.0 in 2025, then dropped by 1.28% to 45440000.0 in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Income from Continuing Operations are 45440000.0 (Q1 2026), 44867000.0 (Q4 2025), and 42049000.0 (Q3 2025).